Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2007081654) COMPOSITIONS AND METHODS TO ENHANCE VIABILITY AND FUNCTION OF ISLET CELLS
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2007/081654 International Application No.: PCT/US2006/062458
Publication Date: 19.07.2007 International Filing Date: 21.12.2006
IPC:
A61K 38/46 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43
Enzymes; Proenzymes; Derivatives thereof
46
Hydrolases (3)
Applicants:
KISS, Zoltan [HU/US]; US (UsOnly)
ZOLTAN LABORATORIES LLC [US/US]; 404 20th Street SW Austin, MN 55912, US (AllExceptUS)
Inventors:
KISS, Zoltan; US
Agent:
D'SOUZA, Tanya ; 90 South Seventh Street 2200 Wells Fargo Center Minneapolis, MN 55402-3901, US
Priority Data:
60/754,41228.12.2005US
60/754,52428.12.2005US
Title (EN) COMPOSITIONS AND METHODS TO ENHANCE VIABILITY AND FUNCTION OF ISLET CELLS
(FR) COMPOSITIONS ET MÉTHODES POUR REHAUSSER LA VIABILITÉ ET LA FONCTION DE CELLULES D'ÎLOT
Abstract:
(EN) This invention uses placental alkaline phosphatase ('PALP'), and other members of the alkaline phosphatase family, to reduce the death and thereby maintain or enhance the viability and function of insulin-producing islet &bgr;-cells including insulin secretion. PALP may be administered to a patient that has received transplanted islet cells to protect the transplanted islets against ROS-mediated attacks by the patient's immune system. Transferrin and other promoters of islet survival may also be used to enhance the effects of PALP on islet viability both in vivo and in vitro.
(FR) La présente invention utilise une phosphatase alcaline placentaire ('PALP'), et d’autres membres de la famille des phosphatases alcalines, afin de réduire la mort et d’ainsi maintenir ou rehausser la viabilité et la fonction de cellules &bgr; d'îlot produisant de l’insuline comprenant une sécrétion d'insuline. Ladite PALP peut être administrée à un patient ayant reçu des cellules d'îlots transplantés pour protéger ces îlots contre des attaques de ROS par le système immunitaire du patient. Une transferrine et autres promoteurs de survie d'îlot peuvent aussi être utilisés pour rehausser les effets de la PALP sur la viabilité d'îlots in vivo comme in vitro.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)